Nanobiotix Raises €86M to Accelerate Cancer Therapy Development
Event summary
- Nanobiotix completed a €86.1M follow-on offering in May 2026 to accelerate development of its therapeutic platforms.
- Phase 2 data for JNJ-1900 (NBTXR3) in Stage 3 NSCLC showed 85.7% overall response rate and 57.1% complete response rate.
- FDA accepted a protocol amendment for the NANORAY-312 study, eliminating interim analysis and accelerating final analysis.
- New preclinical data presented at AACR 2026 showed improved systemic bioavailability and reduced toxicity for Nanoprimer platform.
- Cash position of €42.1M as of March 31, 2026, with runway into 2029.
The big picture
Nanobiotix's €86.1M raise and promising clinical data for JNJ-1900 (NBTXR3) position it as a key player in the cancer therapy space. The company's focus on physics-based nanotherapeutics aligns with the industry's shift towards innovative, targeted treatments. The strategic collaboration with Johnson & Johnson and the FDA's acceptance of the protocol amendment for NANORAY-312 highlight the company's ability to navigate regulatory and commercial challenges.
What we're watching
- Clinical Efficacy
- Whether the promising Phase 2 data for JNJ-1900 (NBTXR3) in NSCLC will translate into successful Phase 3 outcomes.
- Financial Runway
- How Nanobiotix will manage its €42.1M cash position to sustain operations into 2029.
- Regulatory Progress
- The pace at which the FDA will review and approve the amended NANORAY-312 study protocol.
Related topics